US Launches Trade Probe into Germany’s Drug Pricing Policies

Germany’s Drug Pricing Under US Scrutiny

The United States has opened a Section 301 trade investigation into Germany’s pharmaceutical pricing practices, raising concerns that the country’s reimbursement system unfairly disadvantages American drugmakers.

According to the Office of the US Trade Representative (USTR), Germany has consistently underpaid for innovative medicines, limiting revenue for pharmaceutical companies and discouraging investment in research and development. Officials argue that this forces American patients to bear a disproportionate share of global R&D costs, while Germany benefits from lower prices.

What Triggered the Probe

The investigation follows Germany’s recent legislative efforts to fast-track laws aimed at cutting spending on innovative drugs. US officials claim these measures could further reduce incentives for pharmaceutical innovation and place additional burdens on American commerce.

Official Statements

• USTR Jamieson Greer stated: “American patients should not be shouldering a disproportionate share of global pharmaceutical research and development.”
• A Federal Register notice described Germany’s policies as “unreasonable or discriminatory,” adding that they impose significant burdens on US companies.

Next Steps in the Investigation

The USTR will begin collecting public comments from stakeholders and hold a hearing in September 2026. Depending on the findings, the US could impose new tariffs on German goods, escalating trade tensions between the two nations.

Broader Context

This move is part of President Trump’s renewed reliance on trade probes after the Supreme Court struck down several tariff measures earlier in the year. Recently, the USTR also proposed tariffs of up to 12.5% on economies under investigation for forced labor concerns, signaling a broader strategy of aggressive trade enforcement.

Implications

If tariffs are introduced, Germany’s pharmaceutical exports could face significant challenges, while US patients may benefit from efforts to secure fairer global drug pricing. The probe could also reshape international negotiations on how countries share the costs of medical innovation, making it a pivotal moment in US-Germany trade relations.